Men taking valproate advised by MHRA to use effective contraception The regulator advises that males and their partners should use effective contraception during, and for at least three months after, valproate treatment.…
MHRA finds no link between GLP-1 receptor agonists and suicidal behaviour The regulator says it will continue to monitor the risk of severe psychiatric reactions and assess new data as they become available.…
Advantages and disadvantages of shorter antimicrobial courses An overview of the available evidence for shorter antimicrobial courses, including how this can be supported in practice and the potential positive impact on antimicrobial resistance.…
Pharmacies warned to be prepared to support people being released early from prison NHS England has written to community pharmacy leads and GPs to request that they prepare to support people being released early from prison in September and October 2024.…
Prescribing dilemma: balancing risk and benefit when treating sertraline sexual dysfunction The first of a new series of articles exploring real-world dilemmas that pharmacist prescribers encounter in clinical practice.…
NICE recommends emergency kits for people with adrenal insufficiency to cut hospital admissions The new guidance says healthcare providers should consider providing eligible patients with two or three emergency adrenal insufficiency kits.…
Pharmacies have missed out on almost £10m in funding having not met Pharmacy First thresholds Exclusive: Data analysis by The Pharmaceutical Journal has revealed that 9,600 pharmacies in England missed the Pharmacy First consultation threshold between February 2024 and May 2024.…
Pharmacist-led trial to assess impact of outreach on homeless people secures government funding Under the programme, pharmacists and third sector homelessness workers offer outreach to address health and social care needs in people experiencing homelessness.…
Psilocybin may be as effective as escitalopram in treating depression, study suggests A meta-analysis has found similar effectiveness of psilocybin compared with escitalopram in the treatment of depression, but the study does have limitations.…
Alzheimer’s treatment lecanemab too costly for NHS, says NICE draft guidance The National Institute for Health and Care Excellence has determined that the small benefit that lecanemab provides patients in the early stages of Alzheimer’s disease does not justify the cost to the NHS.…
